Estimating the Economic Consequences of Leveraging the Novel cobas HIV-1/HIV-2 Qualitative Nucleic Acid Amplification Test in Routine HIV Testing.

ABSTRACT:

Background

Efficient and cost-effective testing strategies are needed to reduce human immunodeficiency virus (HIV) transmission. The aim of the current study was to compare the costs of using the current Centers for Disease Control and Prevention 3-step HIV algorithm-antigen-antibody screening, differentiation immunoassay (Geenius), and nucleic acid amplification test against an alternative algorithm using a cobas HIV-1/HIV-2 qualitative nucleic acid amplification test.

Methods

A 1-year cost calculator was developed from a US payer perspective using a decision-tree approach to simulate testing in a population of 1 million individuals. An estimated 2.44% of individuals were tested for HIV with an antigen-antibody immunoassay test, of which 0.72% were reactive. Based on real-w

SUBMITTER: Bilir SP 

PROVIDER: S-EPMC12448589 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature